Medivation Gets Good News From Alzheimer’s Trial

Medivation reported positive results for its first confirmatory Phase III clinical trial for Alzheimer’s disease using its investigational drug Dimebon.

Patients with mild-to-moderate Alzheimer’s disease were treated in the double-blind, placebo-controlled trial. Evaluated at six and 12 months, subjects showed improvements in memory and thinking, daily living activities, behavior and overall function.

The drug was well tolerated throughout the trial. No difference was exhibited between the drug and placebo groups in the number of patients who experienced adverse events, the company said.